Literature DB >> 16157694

Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors.

Christian Tränkle1, Andreas Dittmann, Uwe Schulz, Oliver Weyand, Stefan Buller, Kirstin Jöhren, Eberhard Heller, Nigel J M Birdsall, Ulrike Holzgrabe, John Ellis, Hans Dieter Höltje, Klaus Mohr.   

Abstract

The binding and function of muscarinic acetylcholine receptors can be modulated allosterically. Some allosteric muscarinic ligands are "atypical", having steep concentration-effect curves and not interacting competitively with "typical" allosteric modulators. For atypical agents, a second allosteric site has been proposed. Different approaches have been used to gain further insight into the interaction with M2 receptors of two atypical agents, tacrine and the bispyridinium compound 4,4'-bis-[(2,6-dichloro-benzyloxy-imino)-methyl]-1,1'-propane-1,3-diyl-bispyridinium dibromide (Duo3). Interaction studies, using radioligand binding assays and the allosteric ligands obidoxime, Mg2+, and the new tool hexamethonium to antagonize the allosteric actions of the atypical ligands, showed different modes of interaction for tacrine and Duo3 at M2 receptors. A negatively cooperative interaction was observed between hexamethonium and tacrine (but not Duo3). A tacrine dimer that exhibited increased allosteric potency relative to tacrine but behaved like a typical allosteric modulator was competitively inhibited by hexamethonium. M2/M5-receptor mutants revealed a dependence of tacrine and Duo3 affinity on different receptor epitopes. This was confirmed by docking simulations using a three-dimensional model of the M2 receptor. These showed that the allosteric site could accommodate two molecules of tacrine simultaneously but only one molecule of Duo3, which binds in different mode from typical allosteric agents. Therefore, the atypical actions of tacrine and Duo3 involve different modes of receptor interaction, but their sites of attachment seem to be the "common" allosteric binding domain at the entrance to the orthosteric ligand binding pocket of the M2-receptor. Additional complex behavior may be rationalized by allosteric interactions transmitted within a receptor dimer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157694     DOI: 10.1124/mol.105.017707

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

1.  Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.

Authors:  Maren Grossmüller; Johannes Antony; Christian Tränkle; Ulrike Holzgrabe; Klaus Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-12-16       Impact factor: 3.000

2.  A fluorescence resonance energy transfer-based M2 muscarinic receptor sensor reveals rapid kinetics of allosteric modulation.

Authors:  Monika Maier-Peuschel; Nadine Frölich; Christian Dees; Leif G Hommers; Carsten Hoffmann; Viacheslav O Nikolaev; Martin J Lohse
Journal:  J Biol Chem       Date:  2010-01-18       Impact factor: 5.157

3.  Methylacridinium and its cholinergic properties.

Authors:  Ondrej Soukup; Jan Proska; Jiri Binder; Jana Zdarova Karasova; Gunnar Tobin; Daniel Jun; Jan Marek; Kamil Musílek; Josef Fusek; Kamil Kuca
Journal:  Neurotox Res       Date:  2009-06-30       Impact factor: 3.911

4.  Novel allosteric effects of amiodarone at the muscarinic M5 receptor.

Authors:  Edward Stahl; John Ellis
Journal:  J Pharmacol Exp Ther       Date:  2010-03-26       Impact factor: 4.030

5.  Structural model of ligand-G protein-coupled receptor (GPCR) complex based on experimental double mutant cycle data: MT7 snake toxin bound to dimeric hM1 muscarinic receptor.

Authors:  Catherine Marquer; Carole Fruchart-Gaillard; Guillaume Letellier; Elodie Marcon; Gilles Mourier; Sophie Zinn-Justin; André Ménez; Denis Servent; Bernard Gilquin
Journal:  J Biol Chem       Date:  2011-06-17       Impact factor: 5.157

6.  In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage.

Authors:  D Appenroth; M Decker; C Tränkle; K Mohr; J Lehmann; C Fleck
Journal:  Pflugers Arch       Date:  2007-08-24       Impact factor: 3.657

7.  Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach.

Authors:  Anthony Ivetac; J Andrew McCammon
Journal:  Chem Biol Drug Des       Date:  2010-07-05       Impact factor: 2.817

8.  Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors.

Authors:  Suazette Reid Mooring; Jin Liu; Zhongxing Liang; Jeffrey Ahn; Samuel Hong; Younghyoun Yoon; James P Snyder; Hyunsuk Shim
Journal:  ChemMedChem       Date:  2013-03-06       Impact factor: 3.466

9.  Characterization of methanthelinium binding and function at human M1-M5 muscarinic acetylcholine receptors.

Authors:  Matthias Irmen; Janine Holze; Theresa Bödefeld; Christian Tränkle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-24       Impact factor: 3.000

10.  Novel bipharmacophoric inhibitors of the cholinesterases with affinity to the muscarinic receptors M1 and M2.

Authors:  Regina Messerer; Clelia Dallanoce; Carlo Matera; Sarah Wehle; Lisa Flammini; Brian Chirinda; Andreas Bock; Matthias Irmen; Christian Tränkle; Elisabetta Barocelli; Michael Decker; Christoph Sotriffer; Marco De Amici; Ulrike Holzgrabe
Journal:  Medchemcomm       Date:  2017-04-27       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.